Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators.

G Weryha1, V Pascal-Vigneron, M Klein

  • 1Department of Endocrinology, CHU de Nancy, Vandoeuvre, France. weryha@facmed.u-nancy.fr

Current Opinion in Rheumatology
|July 20, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.

European journal of endocrinology·2017
Same author

Unraveling the intrafamilial correlations and heritability of tumor types in MEN1: a Groupe d'étude des Tumeurs Endocrines study.

European journal of endocrinology·2015
Same author

[Evaluation of theoretical teaching of the French diploma of medical gynecology].

Gynecologie, obstetrique & fertilite·2014
Same author

2012 European thyroid association guidelines for the management of familial and persistent sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations.

European thyroid journal·2014
Same author

Patients lost to follow-up in acromegaly: results of the ACROSPECT study.

European journal of endocrinology·2014
Same author

Endocrine disorders in Woodhouse-Sakati syndrome: a systematic review of the literature.

Journal of endocrinological investigation·2014
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Selective estrogen receptor modulators (SERMs) show promise for postmenopausal women, reducing fracture risk and breast cancer incidence without impacting endometrial health. These compounds offer a potential alternative to traditional hormone replacement therapy.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) are nonsteroidal compounds with mixed estrogenic and antiestrogenic effects.
  • Tamoxifen and raloxifene represent key SERMs with distinct tissue-specific actions.
  • Understanding SERM mechanisms is crucial for optimizing menopausal hormone therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of raloxifene in postmenopausal women.
  • To assess the impact of raloxifene on bone health, lipid profiles, and gynecological parameters.
  • To determine raloxifene's effect on breast cancer risk.

Main Methods:

  • Clinical trials involving postmenopausal women treated with raloxifene.
  • Assessment of vertebral fracture incidence.

Related Experiment Videos

  • Monitoring of lipid profiles, including low-density lipoprotein cholesterol and triglycerides.
  • Evaluation of endometrial thickness and breast cancer incidence.

    • Main Results:

    • Raloxifene significantly reduced vertebral fracture risk.
    • Low-density lipoprotein cholesterol levels decreased, while triglyceride levels remained unchanged.
    • No significant change in endometrial thickness was observed.
    • A significant decrease in newly diagnosed breast cancer risk was noted, particularly for estrogen receptor-positive tumors.

    Conclusions:

    • Raloxifene demonstrates beneficial effects on bone and cardiovascular health in postmenopausal women.
    • Raloxifene offers a favorable safety profile regarding endometrial effects.
    • SERMs like raloxifene may represent a valuable therapeutic option for managing menopausal symptoms and reducing breast cancer risk.